Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis

Gynecologic Oncology

Volumn 142, Issue 1, 2016, Pages 38-43

  Rauh Hain, J Alejandro ^a   Gonzalez, Rafael ^a   Bregar, Amy J ^a   Clemmer, Joel ^a   Hernández Blanquisett, Abraham ^a   Clark, Rachel M ^a   Schorge, John O ^a   Del Carmen, Marcela G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinosarcoma; Chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CAUCASIAN; FEMALE; HIGH GRADE PAPILLARY SEROUS OVARY CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MARRIAGE; MIDDLE AGED; OVARY CARCINOMA; OVARY CARCINOSARCOMA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; CANCER GRADING; COMPARATIVE STUDY; CYSTADENOCARCINOMA, SEROUS; EPIDEMIOLOGY; FACTUAL DATABASE; KAPLAN MEIER METHOD; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; DATABASES, FACTUAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84964842848     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.04.025     Document Type: Article

References (26)

1. M.S. Mano, D.D. Rosa, E. Azambuja, G. Ismael, S. Braga, V. D'Hondt, and et al. Current management of ovarian carcinosarcoma Int. J. Gynecol. Cancer 17 2007 316 324
2. A.J. Rauh-Hain, W.B. Grodwon, N. Rodriguez, A.K. Goodman, D. Boruta, and et al. Carcinosarcoma of the ovary: a case-control study Gynecol. Oncol. 121 2011 477 481
3. D. Berton-Rigaud, M. Devouassoux-Shisheboran, J.A. Ledermann, M.M. Leitao, and et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma Int. J. Gynecol. Cancer 24 9 Suppl. 3 2014 S55 S60
4. M.G. del Carmen, M. Birrer, and J.O. Schorge Carcinosarcoma of the ovary: a review of the literature Gynecol. Oncol. 125 1 2012 271 277
5. T.S. Shylasree, A. Bryant, and R. Athavale Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma Cochrane Database Syst. Rev. 2 2013 CD006246
6. J.A. Rauh-Hain, E.J. Diver, J.T. Clemmer, L.S. Bradford, R.M. Clark, and et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis Gynecol. Oncol. 131 1 2013 46 51
7. E.M. George, T.J. Herzog, A.I. Neugut, Y.S. Lu, and et al. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome Gynecol. Oncol. 131 1 2013 42 45
8. M.V. Raval, K.Y. Bilimoria, A.K. Stewart, D.J. Bentrem, and C.Y. Ko Using the NCDB for cancer care improvement: an introduction to available quality assessment tools J. Surg. Oncol. 99 8 2009 488 490
9. J.R. Howe, L.H. Karnell, H.R. Menck, and C. Scott-Conner Adenocarcinoma of the small bowel, review of the National Cancer Data Base, 1985-1995 Cancer 86 12 1999 2693 2706
10. M. Koshy, S.A. Fedewa, R. Malik, and et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA (N2) non-small-cell lung cancer J. Thorac. Oncol. 8 2013 915 922
11. N.M. Rueth, H.Y. Lin, I. Bedrosian, S.F. Shaitelman, N.T. Ueno, Y. Shen, and G. Babiera Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis oftreatment and survival trends from the National Cancer Database J. Clin. Oncol. 32 19 2014 2018 2024
12. A.M. Ganapathi, P.J. Speicher, B.R. Englum, A.W. Castleberry, J. Migaly, D.S. Hsu, and C.R. Mantyh Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit Dis. Colon Rectum 57 12 2014 (1341-18)
13. K. Mallin, B.E. Palis, N. Watroba, and et al. Completeness of American cancer registry treatment data: Implications for quality of care research J. Am. Coll. Surg. 216 3 2013 428 437
14. J. Prat, and FIGO committee on gynecologic oncology Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the International Federation of Gynecology and Obstetrics (FIGO) Obstet. Gynecol. 126 1 2015 171 174
15. S. Raigani, J.M. Hardacre, J. Kim, and J.B. Ammori Trends in the surgical treatment of gastric adenocarcinoma Ann. Surg. Oncol. 21 2 2014 569 574
16. C.N. Klabunde, A.L. Potosky, J.M. Legler, and et al. Development of a comorbidity index using physician claims data J. Clin. Epidemiol. 53 12 2000 1258 1267
17. M.E. Charlson, P. Pompei, K.L. Ales, and et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J. Chronic Dis. 40 5 1987 373 383
18. A.K. Sood, J.I. Sorosky, M.S. Gelder, R.E. Buller, and et al. Primary ovarian sarcoma - analysis of prognostic variables and the role of surgical cytoreduction Cancer 82 1998 1731 1737
19. M.A. Harris, L.M. Delap, P.S. Sengupta, and et al. Carcinosarcoma of the ovary Br. J. Cancer 88 2003 654 657
20. J. Chang, J.C. Sharpe, R.P. A'Hern, C. Fisher, and et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients Ann. Oncol. 8 1995 755 758
21. J. Barholtz-Sloan, C. Bryant, R. Morris, and et al. Survival of women diagnosed with malignant mixed mullerian tumors of the ovary (OMMMT) Gynecol. Oncol. 93 2004 506 512
22. Z. Jin, S. Ogata, G. Tamura, and et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis Int. J. Gynecol. Pathol. 22 2003 368 373
23. A. Schipf, D. Mayr, T. Kirchner, and et al. Molecular genetic aberration of ovarian and uterine carcinosarcomas - a CGH and FISH study Virchows Arch. 452 2008 259 268
24. W.B. Growdon, B.N. Roussel, V.L. Scialabba, and et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin Gynecol. Oncol. 121 2011 212 217
25. C.L. Schwab, D.P. Enlgish, J. Black, and et al. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo Gynecol. Oncol. 139 2015 112 117
26. R. Nicoletti, S. Lopez, S. Bellone, and et al. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 Clin. Exp. Metastasis 32 2015 29 38